Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 71%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

enGene Holdings Inc. is positioned favorably for growth due to its innovative dually derived chitosan (DDX) gene delivery platform, which facilitates localized delivery of gene therapies to mucosal tissues, addressing significant unmet medical needs in non-muscle invasive bladder cancer (NMIBC). The company has achieved a substantial increase in its clinical progression metrics, with detailimogene's six-month complete response (CR) rates aligning with leading assets in the field while benefiting from a superior non-viral profile, thus expanding potential market share, particularly in community practice settings. Furthermore, enGene's strategic focus on advancing its pipeline, alongside a notable increase in research and development expenditures reflecting its commitment to clinical advancements, supports a positive outlook for future revenue growth and market penetration.

Bears say

The ongoing LEGEND trial for detalimogene has shown disappointing performance, compounded by unexpected safety issues and changing regulatory requirements for non-muscle invasive bladder cancer (NMIBC). The introduction of TAR-200 as a competitive alternative presents additional challenges, notably due to its procedural burden and safety metrics, which could hinder enGene’s market penetration. Furthermore, the company is expected to face significant financial pressures, necessitating additional equity financing that may lead to further dilution for shareholders, thus negatively impacting the stock's outlook.

ENGN has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 71% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 7 analysts, ENGN has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $21.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $21.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.